Epithelial Ovarian Cancer
Conditions
Interventions
Drug sensitivity group:Drug sensitivity results of tumor cells derived from ascites assisting chemotherapy regimen decision
Control group:none
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. The participant voluntarily agrees to join the study, signs the informed consent form, has good compliance, and is willing to cooperate with follow-up. 2. Pathologically confirmed diagnosis of epithelial ovarian cancer. 3. Clinical or surgical pathological staging of stage III-IV. 4. Patients who experienced recurrence within one year after cessation of chemotherapy. 5. Sufficient ascites available for collection. 6. Patients not suitable for secondary cytoreductive surgery. 7. An expected survival time of at least 3 months.
Exclusion criteria
Exclusion criteria: 1. Patients with insufficient ascites for collection. 2. Patients who have undergone successful secondary cytoreductive surgery with no residual tumor. 3. Patients with other concurrent malignancies. 4. Patients unable to complete standardized clinical diagnosis and treatment. 5. Patients with incomplete clinical data or who cannot be followed up.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Quality of life patients between two groups;Adverse Effect; | — |
Primary
| Measure | Time frame |
|---|---|
| tumor markers;progression-free survival;Circulatin Tumor Cell;objective response rate; | — |
Countries
China
Contacts
Public ContactJiaxin Yang
Peking Union Medical College Hospital
Outcome results
None listed